Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post by Nikhil Vasudeva, on X, PGY1 Resident at Department of Medicine, AIIMS, adding:
“Denosumab – add it to our list of medications where dose optimization in myeloma may be helpful!
Learning from my colleagues on Twitter and international IMWG colleagues at ASH 2025: Denosumab 120-60 mg Q4W may be sweet spot if CKD, hypoCa concerns, etc!“
Quoting Nikhil Vasudeva’s post:
“We routinely give lower dose at our centre. Works well and very rarely causes hypocalcemia and is pocket friendly for the caregivers.”
More posts from Rahul Banerjee.